Rallybio

Biotechnology
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.

$33.2M

Market Cap • 12/19/2025

2020

(5 years)

Founded

2021

(4 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country